Brewer GJ, Merajver SD.
Cancer therapy with tetrathiomolybdate: antiangiogenesis by lowering body copper--a review.
Integr Cancer Ther. 2002 Dec;1(4):327-37. Review.
PMID: 14664727 [PubMed - indexed for MEDLINE]
Q. Pan, C. G. Kleer, K. L. van Golen, J. Irani, K. M. Bottema, C. Bias, M. De Carvalho, E. A. Mesri, D. M. Robins, R. D. Dick, G. J. Brewer, and S. D. Merajver
Copper Deficiency Induced by Tetrathiomolybdate Suppresses Tumor Growth and Angiogenesis
Canc
B. G. Redman, P. Esper, Q. Pan, R. L. Dunn, H. K. Hussain, T. Chenevert, G. J. Brewer, and S. D. Merajver
Phase II Trial of Tetrathiomolybdate in Patients with Advanced Kidney Cancer
Clin. Cancer Res., May 1, 2003; 9(5): 1666 - 1672.
C. Cox, S. D. Merajver, S. Yoo, R. D. Dick, G. J. Brewer, J. S.-J. Lee, and T. N. Teknos
Inhibition of the Growth of Squamous Cell Carcinoma by
Tetrathiomolybdate-Induced Copper Suppression in a Murine Model
Arch Otolaryngol Head Neck Surg, July 1, 200
Pan Q, Bao LW, Kleer CG, Brewer GJ, Merajver SD.
Antiangiogenic tetrathiomolybdate enhances the efficacy of doxorubicin against breast carcinoma.
Mol Cancer Ther. 2003 Jul;2(7):617-22.
PMID: 12883034 [PubMed - indexed for MEDLINE]
Tetrathiomolybdate promotes tumor necrosis and prevents distant metastases by suppressing angiogenesis in head and neck cancer -- Hassouneh et al. 6 (3): 1039 -- Molecular Cancer Therapeutics
Treatment of Metastatic Cancer with Tetrathiomolybdate, an Anticopper, Antiangiogenic Agent: Phase I Study -- Brewer et al. 6 (1): 1 -- Clinical Cancer Research